Dock-and-Lock Tetrameric Cytokine-Antibody Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies using interferon-α (IFNα) for cancer treatment are limited by its short circulating half-life and systemic toxicity, which results in the need for frequent and high doses, along with significant side effects, while also requiring improved in vivo efficacy and decreased toxicity.
Innovation Solution
The development of cytokine-antibody conjugates using the Dock-and-Lock (DNL) method, where four copies of IFNα2b are attached to a humanized anti-CD20 monoclonal antibody, forming a tetrameric complex that enhances stability and targeting specificity, thereby reducing systemic concentrations and increasing tumor retention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon-α is used for cancer treatment, then anti-tumor activity is improved, but circulating half-life is shortened and systemic toxicity increases
Solution Approach 1:
The patent combines interferon-α with a monoclonal antibody (rituximab) to form an immunocytokine conjugate. This merging allows the interferon to benefit from the antibody's long circulating half-life and target-specific delivery, while maintaining its anti-tumor activity. The conjugate is administered as a single agent rather than separate components.
Solution Approach 2:
The monoclonal antibody serves as an intermediary carrier that delivers interferon-α specifically to tumor cells expressing the target antigen. The antibody mediates both the extended circulation time and the targeted delivery, reducing systemic exposure while increasing tumor-specific concentration of the cytokine.
2Reliability
If interferon-α is used for cancer treatment, then anti-tumor activity is improved, but systemic toxicity and side effects increase
Solution Approach 1:
The immunocytokine conjugate achieves local concentration of interferon-α at the tumor site through antibody-mediated targeting. This localized delivery increases the effective dose at the tumor while reducing systemic circulation levels, thereby improving the therapeutic index and reducing systemic toxicity and side effects.
Solution Approach 2:
The monoclonal antibody acts as a targeted delivery vehicle that directs interferon-α specifically to tumor cells. This intermediary function ensures that the harmful effects of interferon are confined to the tumor microenvironment rather than affecting systemic organs, reducing toxicity.
3Reliability
If interferon-α is used for cancer treatment, then anti-tumor activity is improved, but dosing frequency must be increased
Solution Approach 1:
By merging interferon-α with a monoclonal antibody known for its prolonged circulation, the conjugate inherits the antibody's long half-life characteristics. This allows for less frequent dosing compared to native interferon-α, which requires frequent administration to maintain therapeutic levels.
Solution Approach 2:
The monoclonal antibody intermediary provides sustained circulation and gradual release of interferon-α, extending the duration of therapeutic action. This mediated delivery system maintains effective drug levels for longer periods, reducing the frequency of required administrations.
Data Source
AI summary
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In a most preferred embodiment the complex comprises an anti-CD20 IgG antibody conjugated to four IFN-α2b moieties, although other antibodies and cytokines have been used to form effect DNL complexes.